title: Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion.
abstract: BACKGROUND
  Colorectal cancer (CRC) incidence increases sharply with age. In this study we assessed activity, toxicity and both the activity of daily living (ADL) and instrumental activity of daily living (IADL) of the De Gramont schedule in a series of advanced CRC patients aged > or = 70 years.
  
  
  METHODS
  Sixty-two previously untreated advanced CRC patients entered the study. Median age was 75 (range 70-88).
  
  
  RESULTS
  447 courses were delivered. All of the 62 patients were evaluable for toxicity, 55 for response and ADL-IADL indexes. We recorded 2 complete and 9 partial responses, for an overall response rate of 20%. ADL and IADL indexes improved in 33%, remained stable in 49% and worsened in 18% of evaluable patients. Treatment was very well-tolerated with no serious hematological or non-hematological toxicities.
  
  
  CONCLUSIONS
  The De Gramont schedule was very well tolerated in advanced CRC elderly patients, although our work could not confirm the original reported activity. ADL and IADL indexes improved or remained stable in 82% of evaluable patients.
authors: Medical Oncology Unit, S. Croce Hospital, I-61032 Fano, Italy.
authors: R
authors: R
authors: Mattioli
authors: P
authors: P
authors: Lippe
authors: F
authors: F
authors: Recchia
authors: C
authors: C
authors: Massacesi
authors: L
authors: L
authors: Imperatori
authors: S
authors: S
authors: De Filippis
authors: M
authors: M
authors: Rosselli
authors: P
authors: P
authors: Gattafoni
authors: V
authors: V
authors: Casadei
authors: D
authors: D
authors: Consales
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D016019:Survival Analysis
chemical_list: D002955:Leucovorin; D005472:Fluorouracil